Streetbeat News

IRON

Disc Medicine, Inc.

https://www.discmedicine.com

Industry

Biotechnology

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Open

54.10

Mkt cap

1.9B

Volume

425K

High

55.80

P/E Ratio

-13.81

52-wk high

77.60

Low

54.04

Div yield

N/A

52-wk low

25.60

Williams Sonoma has announced a new exclusive food collaboration with Iron Chef Masaharu Morimoto. This partnership is expected to enhance Williams Sonoma's product offerings and attract culinary enthusiasts.

Portfolio Pulse from

February 19, 2025 | 2:15 pm

Disc Medicine, Inc. (IRON) is showing signs of a potential trend reversal with a hammer chart pattern and upward earnings estimate revisions, suggesting it may be a good time to buy the stock.

Portfolio Pulse from

February 12, 2025 | 4:00 pm

Disc Medicine, Inc. (NASDAQ: IRON) announced a proposed public offering of $200 million in common stock and pre-funded warrants, with an option for underwriters to purchase an additional $30 million. The offering is subject to market conditions.

Portfolio Pulse from

January 21, 2025 | 9:15 pm

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, will present at two upcoming investor conferences. This participation may provide insights into the company's progress and future plans.

Portfolio Pulse from

November 13, 2024 | 1:45 pm

Disc Medicine, Inc. has secured a $200 million non-dilutive debt financing from Hercules Capital, Inc. to support its clinical studies in hematologic diseases.

Portfolio Pulse from

November 08, 2024 | 1:45 pm

Disc Medicine, Inc. (NASDAQ:IRON) will host a conference call on November 4 to discuss feedback from its end-of-Phase 2 FDA meeting for Bitopertin, a treatment for erythropoietic protoporphyria.